# Seneca Therapeutics, Inc.

> Seneca Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic immunotherapeutics built on SVV-001, a non-pathogenic Seneca Valley Virus that selectively replicates in solid-tumor cells expressing the TEM8/ANTXR1 receptor. Founded by oncolytic-virus pioneer Dr. Paul Hallenbeck, the company pairs SVV-001 with immune modulators and checkpoint inhibitors to spark systemic anti-tumor immunity, and is advancing a Phase I/II trial in high-grade neuroendocrine neoplasms while building a pipeline of armed and neo-antigen viral constructs.

- **Founded:** 2015
- **Headquarters:** Philadelphia, Pennsylvania, United States
- **Founders:** Paul L. Hallenbeck (Founder, President & Chief Scientific Officer)
- **Team size:** ~11 employees
- **Products:** SVV-001, SVV-001 + checkpoint blockade, Armed SVV-001 constructs, Neo-antigen precision program, Viral vector / gene therapy
- **Notable:** Built SVV-001 into a platform validated across 30+ preclinical cancer models and three clinical trials with a human safety record., Opened a Phase I/II SVV-001 + nivolumab/ipilimumab trial at University of Miami in April 2025., Closed a $3.9M Series B extension in August 2025, securing runway through 2027.

## Products & services

- **SVV-001** — Lead oncolytic immunotherapeutic - a non-pathogenic Seneca Valley Virus that selectively replicates in tumor cells expressing the TEM8/ANTXR1 receptor. Evaluated in 30+ preclinical models and three clinical trials, with a documented human safety record.
- **SVV-001 + checkpoint blockade** — Phase I/II combination of SVV-001 with the checkpoint inhibitors nivolumab and ipilimumab for high-grade neuroendocrine neoplasms, designed to boost response rates.
- **Armed SVV-001 constructs** — Pipeline of six viral constructs arming SVV with immune-enhancing payloads: SVV-012 (anti PD-L1), SVV-024 (IL-2), SVV-037 (CXCL-9), SVV-044 (TGF-beta decoy), SVV-058 (nitroreductase prodrug), SVV-069 (IL-2/IL-15 fusion).
- **Neo-antigen precision program** — Personalized cancer therapy program that uses SVV's rapid ~two-week development cycle to express patient-specific neo-antigens.
- **Viral vector / gene therapy** — SVV-001 explored as a TEM8-targeting viral vector for gene therapy in solid tumors.

## Achievements

- Built SVV-001 into a platform validated across 30+ preclinical cancer models and three clinical trials with a human safety record.
- Opened a Phase I/II SVV-001 + nivolumab/ipilimumab trial at University of Miami in April 2025.
- Closed a $3.9M Series B extension in August 2025, securing runway through 2027.
- Expanded the pipeline with six armed SVV-001 constructs and a neo-antigen precision-medicine program.
- Presented data (AACR LB039) showing SVV overcomes resistance to checkpoint inhibitors in murine neuroendocrine and melanoma models.

## Latest updates

- **2025-08** — Closed a $3.9M Series B Extension round, providing operating runway through 2027 to complete the ongoing Phase I/II trial.
- **2025-04** — Phase I/II SVV-001 clinical trial opened at the University of Miami, combining SVV-001 with nivolumab and ipilimumab for high-grade neuroendocrine neoplasms (planned 21-30 patients).
- **2021-02** — Announced six new armed SVV-001 constructs targeting TEM8 expression plus a neo-antigen precision-medicine program.

## Links

- Website: https://senecatherapeutics.com
- LinkedIn: http://www.linkedin.com/company/seneca-therapeutics-inc

---

Profile page: https://yespress.io/seneca-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-12